Trevi Therapeutics, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing Haduvio, oral nalbuphine ER, for chronic cough indications including IPF-related chronic cough, non-IPF interstitial lung disease, and refractory chronic cough. Its 8-K filings report financial results, clinical development updates, FDA meeting disclosures, and material events related to the Haduvio program.
The company’s SEC record also includes registration and offering materials for common stock financings, underwriting agreements, and proxy disclosures covering director elections, executive compensation, governance matters, and equity-based compensation. These filings describe Trevi’s capital structure, development-stage operating profile, and public-company governance.
Trevi Therapeutics director Michael Thomas Heffernan received a grant of stock options covering 35,000 shares of common stock. The nonstatutory stock option has an exercise price of $13.45 per share and expires on June 2, 2036. The award was granted for his service as a director and will fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting, as long as he continues serving the company. Following this grant, he holds 35,000 options directly under this award.
New Enterprise Associates–affiliated funds filed Amendment No. 9 to update their ownership in Trevi Therapeutics, Inc. after dilution from additional shares outstanding. As of May 5, 2026, the funds may be deemed to beneficially own 15,074,080 common shares, representing 10.5% of Trevi’s stock.
NEA 16 holds 12,273,280 common shares plus 1,851,852 shares underlying NEA 16 warrants, while NEA 18 Venture Growth Equity holds 948,948 shares. The filing states no reportable transactions by these holders in the last 60 days and describes the position as held for investment purposes, with no specific plans to change Trevi’s control or corporate structure.
FMR LLC amended its Schedule 13G to report beneficial ownership of 8,038,060.69 shares of Trevi Therapeutics common stock, representing 6.3% of the class.
The filing shows Abigail P. Johnson has sole dispositive power over the same share amount, references Exhibit 99 for a 13d-1(k)(1) agreement, and attaches a power of attorney effective April 13, 2026.
Trevi Therapeutics reported a net loss of $13.2 million for the three months ended March 31, 2026, compared with $10.3 million a year earlier, as it advances its chronic cough drug Haduvio. Research and development expenses rose to $9.9 million, driven by Phase 3 preparation in idiopathic pulmonary fibrosis (IPF), Phase 2b work in refractory chronic cough (RCC) and NDA‑supportive studies, while general and administrative costs increased to $5.0 million.
The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities, and subsequently strengthened its balance sheet through an April 2026 underwritten equity offering that generated gross proceeds of $173.4 million and approximately $162 million in net proceeds. Management believes existing resources will fund operations for at least 12 months as Trevi progresses parallel Phase 3 IPF-related chronic cough trials, a Phase 2b RCC trial, a Phase 2b non‑IPF ILD trial and multiple Phase 1 studies.
Trevi Therapeutics, Inc. reported a first quarter 2026 net loss of $13.2 million, or $0.09 per share, as it increased investment in its chronic cough pipeline. Research and development and general and administrative expenses both rose versus the prior-year period.
The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities and then completed an underwritten common stock offering in April 2026 that generated approximately $162 million in net proceeds. Trevi now expects its cash runway to extend into 2030, supporting Phase 3 trials in IPF-related chronic cough, Phase 2b trials in non-IPF ILD-related chronic cough and refractory chronic cough, and a potential FDA submission for Haduvio.
Trevi Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Holders of common stock as of April 6, 2026, when 128,586,792 shares were outstanding, may vote online.
Proposals include electing one Class I director, ratifying Ernst & Young LLP as auditor for 2026, an advisory “say‑on‑pay” vote, and approving an amended and restated 2019 Stock Incentive Plan that adds 8,000,000 shares to the equity pool. Stockholders are also asked to approve doubling authorized common stock from 200,000,000 to 400,000,000 shares. The board unanimously recommends voting in favor of all proposals.
Trevi Therapeutics is offering 11,600,000 shares of common stock at a public offering price of $13.00 per share, for aggregate gross proceeds of $150,800,000. The underwriters have a 30-day option to purchase up to an additional 1,740,000 shares. Net proceeds are estimated at approximately $141.1 million (no exercise) and $162.4 million (full exercise), after deducting underwriting discounts and commissions. The offering is expected to settle on or about April 20, 2026. Shares outstanding were 128,306,056 as of December 31, 2025. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary). Proceeds are intended to fund Haduvio clinical development (Phase 3 IPF program, Phase 2b non-IPF ILD and RCC trials), working capital and general corporate purposes; Trevi states these resources are expected to be sufficient to fund operations through 2029, based on current plans.
Trevi Therapeutics entered an underwriting agreement for an underwritten public offering of 11,600,000 shares of common stock at $13.00 per share, all sold by the company. Underwriters will buy the shares at $12.22 per share, and have a 30-day option to purchase up to 1,740,000 additional shares at the same terms.
Trevi estimates net proceeds of about $141.1 million, or $162.4 million if the option is fully exercised, to be raised under its effective Form S-3 shelf. It estimates cash, cash equivalents and marketable securities of approximately $171.8 million as of March 31, 2026, and believes existing cash plus offering proceeds will fund operations and planned Haduvio clinical trials through 2029, though not commercialization or all indications, so additional capital will still be required.
Trevi Therapeutics is offering $150,000,000 of common stock, subject to completion. The preliminary prospectus supplement states the underwriters have a 30-day option to purchase up to an additional $22,500,000 of shares. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026. The company plans to use proceeds to fund Haduvio clinical development, including two pivotal Phase 3 trials and other trials described in the prospectus supplement.